- Changes in Gene Expression Profiles in Patients with 5q- Syndrome Caused by Lenalidomide TreatmentPublication without faculty affiliation
- Differential Expression of MicroRNAs in CD34+ Cells of 5q- Syndrome2011 | First Faculty of Medicine
- Lenalidomide treatment of patients with 5q- syndrome affects genes located in the TNF pathwayPublication without faculty affiliation
- Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome2015 | First Faculty of Medicine
- Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide2015 | First Faculty of Medicine
- Azacitidine Switch to Lenalidomide Eradicated the TP53/ CDKN2A Co-Mutated Clone and Induced Long-Term Erythroid Response in Del(5q) MDS2019 | First Faculty of Medicine
- Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial2018 | First Faculty of Medicine
- High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide2015 | Faculty of Science